You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Gastroenterology
EoE Burden and Pathophysiology of Type 2 Inflammation
Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.
Learning objectives
Understand the role of different type 2 inflammatory cells (beyond eosinophils), and how cytokines such as IL-4 and IL-13 mediate barrier dysfunction, immune cell trafficking, and esophageal remodeling in EoE
Recognize the impact of EoE on patient burden
Description
Learn about the significant patient burden of EoE and the role of type 2 inflammation in this chronic, progressive disease.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.